AI Reshaping Drug Discovery & R&D The era of slow, billion-dollar drug development is coming to an end, and artificial intelligence is wielding the scalpel. What was once a process that could span 10–15 years, involving numerous false starts and trial-and-error lab work, is now being compressed into a fraction of the time through machine learning, generative algorithms, and multi-agent AI systems. Pharma companies are no longer treating AI as a fancy add-on. Instead, it’s becoming the core operating engine for mapping disease pathways to designing novel molecules that have never existed in nature. For example, AI platforms can now analyze massive datasets of protein structures, patient genomes, and historical trial data to predict which compounds are most likely to succeed before any lab experiment begins. This not only reduces costs but also slashes the environmental footprint of R&D by minimizing wasted resources. In 2025, the World Economic Forum estimates...
